News & Events

KRAS G12V NSCLC: Molecular Profile and ICB Benefit

KRAS G12V NSCLC: Molecular Profile and ICB Benefit

KRAS G12V–Mutated NSCLC: Smoking-Driven Biology and Immunotherapy Sensitivity

KRAS G12V–Mutated NSCLC: Smoking-Driven Biology and Immunotherapy Sensitivity

Setidegrasib shows early promise in KRAS G12D-mutated lung and pancreatic cancers

Setidegrasib shows early promise in KRAS G12D-mutated lung and pancreatic cancers

Setidegrasib shows early promise in KRAS G12D-mutated lung and pancreatic cancers

Setidegrasib shows early promise in KRAS G12D-mutated lung and pancreatic cancers

KRAS G12C NSCLC: Promising Strategy as Cetuximab Boosts KRAS Inhibitor Response

KRAS G12C NSCLC: Promising Strategy as Cetuximab Boosts KRAS Inhibitor Response

Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant

Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant

Stephen Liu: First-Line Immunotherapy in KRAS G12C NSCLC

Stephen Liu: First-Line Immunotherapy in KRAS G12C NSCLC

Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment

Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment